Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis.

Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-7445 (Electronic) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE

Publication: Baltimore, Md. : American Association for Cancer Research
Original Publication: Chicago [etc.]

Neovascularization, Pathologic/*prevention & control ; Prostatic Neoplasms/*prevention & control ; Triterpenes/*pharmacology ; Vascular Endothelial Growth Factor Receptor-2/*antagonists & inhibitors; Angiogenesis Inhibitors/pharmacology ; Animals ; Apoptosis/drug effects ; Blotting, Western ; Cell Line ; Cell Line, Tumor ; Cell Movement/drug effects ; Cell Survival/drug effects ; Dose-Response Relationship, Drug ; Humans ; In Vitro Techniques ; Male ; Medicine, Ayurvedic ; Mice ; Mice, Inbred BALB C ; Neovascularization, Pathologic/metabolism ; Neovascularization, Pathologic/pathology ; Neovascularization, Physiologic/drug effects ; Prostatic Neoplasms/blood supply ; Prostatic Neoplasms/pathology ; Rats ; Rats, Sprague-Dawley ; Signal Transduction/drug effects ; Vascular Endothelial Growth Factor A/pharmacology ; Vascular Endothelial Growth Factor Receptor-2/metabolism

The role of angiogenesis in tumor growth and metastasis is well established. Identification of a small molecule that blocks tumor angiogenesis and is safe and affordable has been a challenge in drug development. In this study, we showed that acetyl-11-keto-beta-boswellic acid (AKBA), an active component from an Ayurvedic medicinal plant (Boswellia serrata), could strongly inhibit tumor angiogenesis. AKBA suppressed tumor growth in the human prostate tumor xenograft mice treated daily (10 mg/kg AKBA) after solid tumors reached approximately 100 mm(3) (n = 5). The inhibitory effect of AKBA on tumor growth was well correlated with suppression of angiogenesis. When examined for the molecular mechanism, we found that AKBA significantly inhibited blood vessel formation in the Matrigel plug assay in mice and effectively suppressed vascular endothelial growth factor (VEGF)-induced microvessel sprouting in rat aortic ring assay ex vivo. Furthermore, AKBA inhibited VEGF-induced cell proliferation, chemotactic motility, and the formation of capillary-like structures from primary cultured human umbilical vascular endothelial cells in a dose-dependent manner. Western blot analysis and in vitro kinase assay revealed that AKBA suppressed VEGF-induced phosphorylation of VEGF receptor 2 (VEGFR2) kinase (KDR/Flk-1) with IC(50) of 1.68 micromol/L. Specifically, AKBA suppressed the downstream protein kinases of VEGFR2, including Src family kinase, focal adhesion kinase, extracellular signal-related kinase, AKT, mammalian target of rapamycin, and ribosomal protein S6 kinase. Our findings suggest that AKBA potently inhibits human prostate tumor growth through inhibition of angiogenesis induced by VEGFR2 signaling pathways.

Oncol Rep. 2008 Oct;20(4):713-9. (PMID: 18813808)
Indian J Exp Biol. 2006 Feb;44(2):128-32. (PMID: 16480179)
Br J Cancer. 2000 Jul;83(1):1-5. (PMID: 10883659)
Clin Cancer Res. 2008 Jun 1;14(11):3589-97. (PMID: 18519793)
Cancer Res. 2008 Mar 15;68(6):1843-50. (PMID: 18339865)
Vascul Pharmacol. 2007 May;46(5):333-7. (PMID: 17257903)
Curr Med Chem. 2006;13(28):3359-69. (PMID: 17168710)
Br J Cancer. 1999 May;80(5-6):756-65. (PMID: 10360653)
BMC Biochem. 2002 Dec 31;3:32. (PMID: 12509223)
Mol Pharmacol. 1995 Jun;47(6):1212-6. (PMID: 7603462)
J Immunol. 2006 Mar 1;176(5):3127-40. (PMID: 16493072)
Cancer Res. 2008 Jan 1;68(1):227-35. (PMID: 18172315)
Nature. 2005 Dec 15;438(7070):967-74. (PMID: 16355214)
Rinsho Ketsueki. 2008 Oct;49(10):1451-9. (PMID: 18833929)
J Immunol. 2005 Jan 1;174(1):498-506. (PMID: 15611276)
Cancer Res. 2008 Oct 1;68(19):8183-8. (PMID: 18829578)
J Pharmacol Exp Ther. 1992 Jun;261(3):1143-6. (PMID: 1602379)
Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):343-7. (PMID: 18855647)
Cell. 2000 Feb 4;100(3):293-6. (PMID: 10676810)
Curr Clin Pharmacol. 2008 May;3(2):132-43. (PMID: 18690886)
J Biol Chem. 2005 Sep 30;280(39):33262-9. (PMID: 16006559)
Clin Cancer Res. 2006 Sep 1;12(17):5018-22. (PMID: 16951216)
Int J Mol Med. 2007 Jul;20(1):113-21. (PMID: 17549397)
Anticancer Res. 2002 Sep-Oct;22(5):2853-62. (PMID: 12530009)
Med Res Rev. 2006 Jul;26(4):483-530. (PMID: 16652370)
Cancer Res. 2008 Feb 15;68(4):1180-6. (PMID: 18281494)
Nature. 2005 Dec 15;438(7070):932-6. (PMID: 16355210)
Carcinogenesis. 2002 Dec;23(12):2087-93. (PMID: 12507932)
Cell. 2000 Jan 7;100(1):57-70. (PMID: 10647931)
Nat Rev Cancer. 2008 Nov;8(11):851-64. (PMID: 18846101)
Cancer Detect Prev. 2003;27(1):67-75. (PMID: 12600419)
J Pharmacol Sci. 2005 Jun;98(2):130-41. (PMID: 15937404)
Eur J Cancer. 2007 Jul;43(11):1748-54. (PMID: 17570654)
Cancer Treat Res. 2004;117:3-32. (PMID: 15015550)
Curr Top Med Chem. 2007;7(14):1379-93. (PMID: 17692027)
Semin Oncol. 2006 Aug;33(4):392-406. (PMID: 16890795)
Int J Mol Med. 2002 Oct;10(4):501-5. (PMID: 12239601)
J Pharmacol Exp Ther. 1997 Apr;281(1):460-3. (PMID: 9103531)
J Biochem Mol Biol. 2006 Sep 30;39(5):469-78. (PMID: 17002866)
Oncogene. 2009 Jan 22;28(3):313-24. (PMID: 18978810)
Cancer Res. 2009 Jan 15;69(2):518-25. (PMID: 19147565)
Curr Opin Cell Biol. 2006 Oct;18(5):516-23. (PMID: 16919435)

R01 CA106479 United States CA NCI NIH HHS; R01 CA106479-05 United States CA NCI NIH HHS; 1R01CA106479 United States CA NCI NIH HHS

0 (11-keto-boswellic acid)
0 (Angiogenesis Inhibitors)
0 (Triterpenes)
0 (Vascular Endothelial Growth Factor A)
EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-2)

Date Created: 20090702 Date Completed: 20090925 Latest Revision: 20211020

20221213

PMC2724674

10.1158/0008-5472.CAN-09-0755

19567671